The specificity of the anti‐human EGFL7 antibody applied was confirmed by costaining of glioma specimens with alternative anti‐EGFL7 antibodies from different sources which yielded 100% overlap (Appendix Fig S1F). This evidence concerns the gene EGFL7 and central nervous system cancer.